Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Operative Nausea And Vomiting - Pipeline Review, H2 2016, provides an overview of the Post Operative Nausea And Vomiting (Gastrointestinal) pipeline landscape.
Postoperative nausea and vomiting (PONV) is one of the commonest complaints following anaesthesia, and can result in morbidity like wound dehiscence, bleeding, pulmonary aspiration of gastric contents, fluid and electrolyte disturbances, delayed hospital discharge, unexpected hospital admission, and decreased patient satisfaction. The thorough understanding of the mechanism of nausea and vomiting and a careful assessment of risk factors provide a rationale for appropriate management of PONV. This multimodal PONV management approach includes use of: (i) multiple different antiemetic medications (double or triple combination antiemetic therapy acting at different neuroreceptor sites); (ii) less emetogenic anaesthesia techniques; (iii) adequate intravenous hydration; and (iv) adequate pain control.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post Operative Nausea And Vomiting - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Post Operative Nausea And Vomiting (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Post Operative Nausea And Vomiting (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Post Operative Nausea And Vomiting and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Unknown stages are 2, 1, 1 and 1 respectively.Post Operative Nausea And Vomiting.
Post Operative Nausea And Vomiting (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Post Operative Nausea And Vomiting (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Post Operative Nausea And Vomiting (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post Operative Nausea And Vomiting (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post Operative Nausea And Vomiting (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post Operative Nausea And Vomiting (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post Operative Nausea And Vomiting (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post Operative Nausea And Vomiting (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Acacia Pharma Ltd
Camurus AB
GW Pharmaceuticals Plc
INSYS Therapeutics Inc
Suda Ltd
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Post Operative Nausea And Vomiting Overview 6
Therapeutics Development 7
Pipeline Products for Post Operative Nausea And Vomiting - Overview 7
Post Operative Nausea And Vomiting - Therapeutics under Development by Companies 8
Post Operative Nausea And Vomiting - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Unknown Stage Products 11
Post Operative Nausea And Vomiting - Products under Development by Companies 12
Post Operative Nausea And Vomiting - Companies Involved in Therapeutics Development 13
Acacia Pharma Ltd 13
Camurus AB 14
GW Pharmaceuticals Plc 15
INSYS Therapeutics Inc 16
Suda Ltd 17
Post Operative Nausea And Vomiting - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 27
(buprenorphine hydrochloride + granisetron hydrochloride) - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
amisulpride - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
nabiximols - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
ondansetron hydrochloride - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
ondansetron hydrochloride - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Post Operative Nausea And Vomiting - Dormant Projects 41
Post Operative Nausea And Vomiting - Discontinued Products 42
Post Operative Nausea And Vomiting - Product Development Milestones 43
Featured News & Press Releases 43
Aug 12, 2016: Positive Results From Pivotal Phase 3 Trial of BAREMSIS For The Treatment of PONV 43
Mar 21, 2016: Initiation of Second Pivotal Phase 3 Treatment Trial with BAREMSIS (APD421) in PONV 43
Jan 05, 2016: Positive Results From Second Pivotal Phase 3 Study Of BAREMSIS (APD421) In PONV 44
Apr 21, 2015: Phase 3 Combination Prophylaxis Study Initiated With APD421 In PONV 45
Oct 07, 2014: Acacia Pharma Announces Positive Phase 3 Results For APD421 in Post-Operative Nausea & Vomiting 46
Sep 17, 2013: Acacia Pharma Initiates Pivotal Phase 3 Studies with APD421 in Post-Operative Nausea & Vomiting 46
May 28, 2012: Acacia Pharma Announces Positive Results For APD421 In Post-Operative Nausea & Vomiting 47
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50
List of Tables
Number of Products under Development for Post Operative Nausea And Vomiting, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Unknown Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Post Operative Nausea And Vomiting - Pipeline by Acacia Pharma Ltd, H2 2016 13
Post Operative Nausea And Vomiting - Pipeline by Camurus AB, H2 2016 14
Post Operative Nausea And Vomiting - Pipeline by GW Pharmaceuticals Plc, H2 2016 15
Post Operative Nausea And Vomiting - Pipeline by INSYS Therapeutics Inc, H2 2016 16
Post Operative Nausea And Vomiting - Pipeline by Suda Ltd, H2 2016 17
Assessment by Monotherapy Products, H2 2016 18
Assessment by Combination Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 26
Post Operative Nausea And Vomiting - Dormant Projects, H2 2016 41
Post Operative Nausea And Vomiting - Discontinued Products, H2 2016 42
List of Figures
Number of Products under Development for Post Operative Nausea And Vomiting, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 10
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Targets, H2 2016 20
Number of Products by Stage and Targets, H2 2016 20
Number of Products by Mechanism of Actions, H2 2016 22
Number of Products by Stage and Mechanism of Actions, H2 2016 22
Number of Products by Routes of Administration, H2 2016 24
Number of Products by Stage and Routes of Administration, H2 2016 24
Number of Products by Stage and Molecule Types, H2 2016 26
